It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cutaneous leishmaniasis is the most prevalent form of leishmaniasis worldwide. Although various anti-leishmanial regimens have been considered, due to the lack of efficacy or occurrence of adverse reactions, design and development of novel topical delivery systems would be essential. This study aimed to prepare artemether (ART)-loaded niosomes and evaluate their anti-leishmanial effects against Leishmania major. ART-loaded niosomes were prepared through the thin-film hydration technique and characterized in terms of particle size, zeta potential, morphology, differential scanning calorimetry, drug loading, and drug release. Furthermore, anti-leishmanial effect of the preparation was assessed in vitro and in vivo. The prepared ART-loaded niosomes were spherical with an average diameter of about 100 and 300 nm with high encapsulation efficiencies of > 99%. The results of in vitro cytotoxicity revealed that ART-loaded niosomes had significantly higher anti-leishmanial activity, lower general toxicity, and higher selectivity index (SI). Half-maximal inhibitory concentration (IC50) values of ART, ART-loaded niosomes, and liposomal amphotericin B were 39.09, 15.12, and 20 µg/mL, respectively. Also, according to the in vivo study results, ART-loaded niosomes with an average size of 300 nm showed the highest anti-leishmanial effects in animal studies. ART-loaded niosomes would be promising topical drug delivery system for the management of cutaneous leishmaniasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shiraz-Marvdasht Hwy, Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Student Research Committee, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
2 Shiraz University of Medical Sciences, Department of Medical Parasitology and Mycology, School of Medicine, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
3 Shiraz University of Medical Sciences, Department of Pharmaceutics, School of Pharmacy, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
4 Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
5 Shiraz-Marvdasht Hwy, Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Department of Pharmaceutics, School of Pharmacy, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)